CUVL (CUVL) Stock Price & Analysis
CUVL (CUVL) rose 0.00% to USD 6.95 as of July 26, 2026 at 08:55 UTC, according to Nexqual real-time market data.
CUVL last closed at USD 6.95; the session ranged USD 6.95–6.95 on volume of 440 shares. Market capitalization is $350.47M, with a 52-week range of USD 6.95–8.19 (NMS). Source: Nexqual, July 26, 2026 at 08:55 UTC.
Key Statistics (as of July 26, 2026 at 08:55 UTC)
| Price | USD 6.95 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 6.95 |
| Open | USD 7 |
| Day Range | USD 6.95 – 6.95 |
| 52-Week Range | USD 6.95 – 8.19 |
| Volume | 440 shares |
| Market Cap | $350.47M |
| Exchange | NMS |
Analyst Ratings (CUVL)
Wall Street analysts rate CUVL "None", per Nexqual as of July 26, 2026 at 08:55 UTC.
| Consensus Rating | None |
|---|
Earnings (CUVL)
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Financials & Fundamentals (CUVL)
| Total Revenue | $96.30M |
|---|---|
| Revenue Growth (YoY) | +3.60% |
| Gross Margin | +89.63% |
| Operating Margin | +36.59% |
| Profit Margin | +33.79% |
| ROE | +13.96% |
| Debt / Equity | 0.13 |
| Current Ratio | 14.64 |
| Total Cash | $233.00M |
| Total Debt | $323,843 |
| Free Cash Flow | $32.20M |
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Financial Health Score (CUVL)
Nexqual rates CUVL's overall financial health "Strong" across five dimensions, as of July 26, 2026 at 08:55 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 90%, operating 37% |
| Balance Sheet | Strong — $233M cash, no debt |
| Cash Flow | Strong — FCF $32M, 34% margin |
| Efficiency | Mixed — ROE 14%, ROA 10.6% |
Ownership (CUVL)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 50.43M |
| Float | 43.65M |
Source: Nexqual, July 26, 2026 at 08:55 UTC.
Leadership (CUVL)
CUVL is led by Philippe Jacques Wolgen (age 62), CEO, MD & Director, per Nexqual as of July 26, 2026 at 08:55 UTC.
| CEO, MD & Director | Philippe Jacques Wolgen (age 62) |
|---|---|
| Chief Financial Officer | Peter Vaughan |
| Chief Scientific Officer | Dennis J. Wright BPharm, M.Sc. |
| Director of North American Operations | Linda Teng |
| Director of Global Clinical Affairs | Emilie Rodenburger |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLVLF | Clinuvel Pharmaceuticals Ltd. | USD 6.1 | ▲ 0% |
| CUV.AX | CLINUVEL FPO [CUV] | AUD 10.06 | ▲ 1.82% |
| SPHRY | Starpharma Holdings Ltd. | USD 4.62 | ▲ 4.76% |
| CSLLY | CSL Ltd. | USD 20 | ▼ 3.85% |
| CMSQY | Computershare Ltd. | USD 27.59 | ▼ 1.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:55 UTC. This page is informational and not investment advice.